Skip to main content

Table 3 Comparison between the 19th Nationwide survey and the first cohort

From: Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study

  19th Nationwide survey n; % First cohort group n; % p-value Odds ratio 95% CI
Total 20,475; 100.0 126; 100   (crude)  
Initial IVIG therapy 17,613; 86.0 101; 80.2 0.06 0.91 0.53–1.57
    0.38* 1.07* 0.88 – 1.30*
Acute phase CAL 2,446; 11.9 6; 4.8 < 0.01 2.71 1.19– 6.17
Cardiac sequelae 772; 3.8 0; 0 < 0.05 0 NA
Additional IVIG therapy 2,860; 14.0 9; 7.1 0.03 2.08 1.06–4.13
  1. CI: confidence interval; CAL: coronary artery lesions.
  2. NA, unable to be calculated because the number contained “0.”
  3. *Adjusted odds ratio for dosage of initial IVIG therapy in both groups was obtained using the Mantel-Haenstzel method adjusted for various initial dosages of intravenous immunoglobulin (2 g/kg, 1 g/kg, 400 mg/kg, or various dosages of IVIG). Adjusted odds ratio for acute-phase CAL, cardiac sequelae, and additional IVIG therapy were not analyzed because there were no descriptions of dosages of various initial IVIG in the nationwide surveys.